The eye disease treatment developer has raised $48m in funding from investors including Santen Pharmaceutical, which is also a research partner.
Clearside Biomedical, a US-based biopharmaceutical company backed by pharmaceutical company Santen Pharmaceutical, has filed for an initial public offering on Nasdaq that could raise up to $57.5m.
Founded in 2011, Clearside is developing treatments for blinding diseases of the eye, particularly those that affect the retina and choroid. The proceeds will fund a phase 3 trial for its most advanced drug candidate and a phase 2 trial for another.
The company has raised approximately $48m in venture funding, closing…
